Navigation Links
Echo Therapeutics, Inc. Announces 2011 Financial Results
Date:3/16/2012

f="http://www.twitter.com/echotx">www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotxEcho Therapeutics, Inc.Condensed Consolidated Balance SheetsDecember 31,2011December 31,2010ASSETSCurrent Assets:Cash and cash equivalents

$
8,995,571$
,342,044Other current assets

567,940621,693Total current assets

9,563,5111,963,737Net property and equipment (including assets under capitalized leases)

317,73148,034Other Assets:Intangible assets, net of accumulated amortization

9,625,0009,625,000Restricted cash, deposits and other assets

20,565275,499Total other assets

9,645,5659,900,499Total assets

$  19,526,807$  11,912,270LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

$
365,298$
5,634Deferred revenue

123,708405,454Derivative warrant liability

1,035,3371,544,996Accrued expenses and other liabilities

968,120565,546Total current liabilities

2,492,4633,121,630Deferred revenue, notes payable and capital lease obligation, net of current portion

65,75588,356Total liabilities

2,558,2183,209,986CommitmentsStockholders' Equity:Perpetual redeemable preferred stock, Series B

-2Convertible preferred stock, Series C & D

30,16049Common stock

385,442311,264Additional paid-in capital

98,116,32779,646,385Common stock subscribed for but not paid for or issued

6,667285,000Accumulated deficit

(81,570,007)(71,540,416)Total stockholders' equity

16,968,5898,702,284Total liabilities and stockholders' equity

$  19,526,807$  11,912,270Condensed Consolidated Statements of OperationsYears Ended December 31,20112010Licensing revenue

$
302,059$
225,868Other revenue

145,152202,592Total revenues

447,211428,460Operating Expenses:Research and development

3,796,1272,578,852Selling, general a
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... March 5, 2015  BioPhotas, Inc., an FDA registered ... patented photo-therapeutic technologies to treat skin, muscle and joint ... Semper Fi Fund to provide BioPhotas, flagship product, the ... pain management solutions.  Commenting on the ... who used the Celluma at the Warrior Hope and ...
(Date:3/5/2015)... 5, 2015   ndd Medical Technologies , a ... employs precise ultrasound technology, announced that its EasyOne Pro® ... the San Antonio Pulmonary Fibrosis Support Group. The clinic ... fibrosis (PF), as well as those suspected of having ... a mere 12 square inches, EasyOne Pro provides accurate ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... filtration devices to address infectious disease and cancer, ... entitled: " A Platform to Address Bioterrorism." ... at: http://www.aethlonmedical.com/knowledge-center/special-reports/ ...
... 2010 Northwestern Memorial Hospital is one ... will test whether operable lung cancer patients and their ... by hardwiring data systems to reduce medical error and ... trial co-sponsored by the Commission on Cancer and the ...
Cached Medicine Technology:'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 2'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 3'A Platform Technology to Address Bioterrorism' Released by Aethlon Medical, Inc. 4Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 2Lung Cancer Patients the Centerpiece for Northwestern Medicine Quality of Care Study 3
(Date:3/6/2015)... CHICAGO (PRWEB) March 06, 2015 As ... and healthcare services programs, the organization has hired two ... Hagerty, Ph.D. They will report to Grace Pavlath, ... Vice President and Scientific Program Director, and together will ... lead to treatments and cures for various types of ...
(Date:3/6/2015)... Parents need to start the discourse with their children ... programs like DARE, or Drug Abuse Resistance Education proved ... Prevention and Education has already impacted a collective 600,000 ... Feb. 27th. As teens continue to suffer fatal overdoses ... are lobbying Florida to pass The Overdose Prevention Act- ...
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... 06, 2015 Since Medicare began paying ... there has been an overwhelming demand from providers for ... compliant CCM program. The Centers for Medicare & ... , PYA’s updated white paper—“ Providing and Billing ... into a detailed, yet practical “how to” manual for ...
(Date:3/6/2015)... Jvion, the Atlanta-based leader in clinical ... Difficile (C Diff) predictive use case for inpatient ... is the latest in a broad compliment of ... conditions, and individual illnesses. Using the firm’s RevEgis ... at risk individuals to help support clinician decision-making ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Nov. 28 Neurobiological,Technologies, Inc (NTI (TM)) (Nasdaq: ... was appointed Chief Medical Officer, effective as of,November ... February 2007 as Vice President, Clinical,Programs with primary ... NTI,s drug candidate for acute ischemic stroke that ...
... Nov. 28 Novant Health(R) today announced ... leader,in developing and manufacturing medical devices for ... implement the Cardiocom System in its,Presbyterian Heart ... Hospital is one of the largest healthcare ...
... Nov. 28 Amedisys, Inc.,(Nasdaq: "AMED" or the "Company"), ... that Larry R. Graham, President and,Chief Operating Officer, and ... 2007 BMO Capital Markets Focus on Healthcare Conference in,New ... will begin at 2:30 p.m. Eastern time. The audio,presentation ...
... WEIFANG, China, Nov. 27 /Xinhua-PRNewswire-FirstCall/ -- Shengtai,Pharmaceutical, Inc. (OTC ... manufacturer and distributor of high-quality,pharmaceutical grade glucose products in ... presenting at the Roth Capital Phoenix,Conference on November 29, ... Company,s presentation at the,conference are as follows:, ...
... should focus on "dementia red flags" rather than ... they,ve reached a certain age, according to Malaz Boustani, ... and the Regenstrief Institute, Inc. and colleagues from the ... the United Kingdom in a commentary published in the ...
... Nov. 27 S*BIO Pte Ltd today announced ... development,candidate, SB1317. This is a novel orally-available small ... SB1317 is designed to selectively inhibit major ... progression in acute,leukemias. Flt3 mutations are the most ...
Cached Medicine News:Health News:Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program 2Health News:Amedisys to Present at 2007 BMO Capital Markets Focus on Healthcare Conference in New York 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference 2Health News:Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference 3Health News:Dementia screening in primary care: Is it time? 2Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2
The Ahmed Glaucoma Valve has been successfully demonstrated to work in all types of glaucoma cases, particularly neovascular, congenital and uvietic glaucoma....
Ahmed Glaucoma Valve Flexible Plate ....
... a robust and durable drainage system. Preplaced ... globe. Pressure Ridge Molteno Implants have a ... tissue, acts as a Pressure sensitive biological ... implants allows the surgeon to choose the ...
... Baerveldt Glaucoma Implants feature a low implant ... reduced complications. The single-quadrant insertion is technically ... seton plate to be installed with less ... fenestrations of the Baerveldt implant were designed ...
Medicine Products: